Currently, kidney disease affects up to 20% of the US population and is a strong contributor to morbidity and mortality in these patients. Specific therapies and diagnostic tools for kidney disease have been very slow to develop because of the absence of high quality samples and data that can be used for research studies. The purpose of this study is to develop a registry and sample bank called Poseidon (Prevention, Optimizing Safety, Early Intervention and DetectiOn in Nephrology) biobank that can be used for future research. In this study, patients can consent to donating their residual kidney tissue if they undergo a kidney biopsy and blood or urine during routine clinical care procedures. This study will allow biomedical research the ability to obtain specimens from patients with relevant diseases and appropriate clinical data. This study will collect patient demographic, clinical and historical data for a registry and patient samples will be deposited in the Poseidon biobank. Patients do not have to be diagnosed with Kidney Disease to be included in this study.
This study is for adult males and females with advanced or metastatic kidney cancer. Researchers want to find out what effects, good and/or bad, two study drugs called sunitinib and cabozantinib have on you and on advanced or metastatic kidney cancer. Sunitinib has been approved by the FDA and cabozantinib is an investigational drug. Both medications target special proteins that are on the surface of the kidney cancer cell and both drugs are taken by mouth.
This study is for individuals with renal cell carcinoma (RCC). The purpose of this study is:
•To find out whether the study treatment can stop your RCC from growing, or prevent it from growing as fast as it would without dalantercept.
•To evaluate the safety of the study treatment in subjects with RCC.
•To find out if the study treatment has an effect on biomarkers (molecules that indicate how well you respond to study treatment) in your blood and/or tissue.
Participants will receive a dose of dalantercept or placebo (a substance with inactive drug that looks the same as dalantercept) plus axitinib. It is expected that a participant will be on this study for a variation of time (total duration will vary per subject).
The purpose of this study is to investigate sphingolipids, a very biologically active class of lipids transported in lipoproteins, in patients with diabetes who have kidney disease (nephropathy). Lipoproteins are particles in blood which transport not only cholesterol and fats but also sphingolipids. Lipoproteins also play an important role in the development of diabetes complications, including nephropathy. This study will investigate the role of the sphingolipids in VLDL (Very Low Density Lipoprotein), LDL (Low Density Lipoprotein) and HDL (High Density Lipoprotein) in the development of nephropathy in diabetes.
This randomized phase II clinical trial is studying giving sunitinib malate together with or without gemcitabine hydrochloride to see how well they work in treating patients with advanced kidney cancer that cannot be removed by surgery. Patients will be Randomized (put into a group by chance) into 2 groups. Group A will receive gemcitabine and Sunitinib. Group B will receive Sunitinib. Treatment cycles are 42 days long and will be repeated for total of 12 months. Follow-up will continue until patients have been on study for 3 years
Overwhelming evidence exists that some types of proteinuric kidney diseases are causerd by factor(s) present in patients' blood. Identification and characterization of such factor(s) would greatly help in beter and noninvasive diagnosis of such conditions, development of better therapeutic options and potentially reveal underlying pathogenic mechanisms.
Owing to tremendous capabilities of proteomics facility within the Division of Nephrology we developed experiments that we think will result in significant improvement in our knoledge of major kidney diseases.
If you are an adult with Autosomal Dominant Polycystic Kidney Disease you may be eligible to take part in a clinical research study.
The purpose of this study is to find the potential benefits and safety of an investigational drug called tolvaptan in adults with Autosomal Dominant Polycystic Kidney Disease. If eligible, the study will involve 25 visits over a period of 15 months. Study drug, study visits, blood work and study procedures will be provided free of charge to qualified participants.
Adult and Pediatric patients with glomerular disease:
Patients of all ages are needed to participate in a research study to investigate glomerular disease and create a worldwide database to help in the research and future treatment of this disease. To join this study, you must have a type of glomerular disease, have had a first kidney biopsy within the last 5 years, not be on on dialysis, or have had a kidney transplant.
The study is projected to last 4 years, and all study procedures will be done at regular clinic visits (between 1 and 3 yearly). Study procedures include filling out questionnaires and a blood draw at each visit.
Compensation is available for study participation.
End stage renal disease patients on dialysis will be screened and asked to participate in a health literacy survey during regular dialysis treatment days. Two health literacy survey tools will be used: The Newest Vital Sign which is a six-question nutritional label format health literacy tool and the Short Health Literacy Survey, a 3 question health literacy tool.
Nutritional and anthropometric parameters normally collected as part of the hemodialysis treatment will be obtained
If you are an adult with type 2 diabetes mellitus and chronic kidney disease (diabetic nephropathy), you may be eligible to take part in a clinical research study called SONAR.
The purpose of this study is to find out if an investigational drug called atrasentan slows the progression of chronic kidney disease. Qualified participants will be randomly assigned to take either atrasentan by mouth or placebo (inactive pill). Study medication, study visits, blood work and study procedures will be provided free of charge.